Risk of major adverse cardiovascular events with dolutegravir versus efavirenz-based antiretroviral therapy: emulated target trials using routine, de-identified data from South Africa

Preprint

Background Integrase inhibitors, including dolutegravir, may increase risk of major adverse cardiovascular events (MACEs). However, limited data exists from low- and middle-income countries, where tenofovir disoproxil fumarate, lamivudine and dolutegravir (TLD) has largely replaced tenofovir disoproxil fumarate, emtricitabine and efavirenz (TEE).

Methods We used de-identified data from a South African managed-healthcare organisation from people living with HIV (PLHIV) without cardiovascular disease, who either initiated TEE or TLD between April 2020-Dec 2023 (initiation cohort) or were receiving TEE in April 2020 and eligible for TLD (transition cohort). In the initiation cohort, we emulated a target trial using pooled logistic regression models with inverse probability of treatment weights and bootstrapped confidence intervals to compare standardised 3-year MACE risk between TLD versus TEE. In the transition cohort, we used similar methods in 44 emulated monthly sequential trials, comparing MACE risk in people transitioned to TLD with those remaining on TEE.

Findings In the initiation cohort, 7310 PLHIV initiated TLD (n=3711) or TEE (n=3599). Median follow-up was 21 months (IQR 10-33), with 18 MACEs with TLD (3-year risk 0.78%, 95%CI 0.37-1.32) and 28 with TEE (3-year risk 0.96%, 0.60-1.40; RR 0.81, 0.35-1.59; RD −0.18, −0.82-0.50). In the transition cohort, 22338 people contributed to 2837 person-trials with TLD and 706615 with TEE. Median follow-up was 25 months (14-36), with 19 MACEs with TLD (3-year risk 1.09%, 0.48-1.99) and 5420 with TEE (3-year risk 1.21%, 1.05-1.41; RR 0.90, 0.41-1.64; RD −0.12, −0.75-0.75).

Interpretation Among PLHIV in South Africa we found no increased MACE with TLD.

Authors: Dorward, J; Masombuka, X; Lewis, L; Pastellides, C; van der Molen, J

• Publication status: Published
• Peer review status: Not peer reviewed
• Preprint server: medRxiv
• Publication date: 2025-03-10
• DOI: 10.1101/2025.03.07.25323562
• Language: English
• Keywords: South Africa; HIV; dolutegravir; antiretroviral therapy; cardiovascular disease